Future directions in early cystic fibrosis lung disease research: An NHLBI workshop report

Bonnie W. Ramsey, Susan Banks-Schlegel, Frank J. Accurso, Richard C. Boucher, Garry R Cutting, John F. Engelhardt, William B Guggino, Christopher L. Karp, Michael R. Knowles, Jay K. Kolls, John J. LiPuma, Susan Lynch, Paul B. McCray, Ronald C. Rubenstein, Pradeep K. Singh, Eric Sorscher, Michael Welsh

Research output: Contribution to journalArticle

Abstract

Since the 1989 discovery that mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF), there has been substantial progress toward understanding the molecular basis for CF lung disease, leading to the discovery and development of new therapeutic approaches. However, the earliest impact of the loss of CFTR function on airway physiology and structure and its relationship to initial infection and inflammation are poorly understood. Universal newborn screening for CF in the United States represents an unprecedented opportunity for investigating CF clinical manifestations very early in life. Recently developed animal models with pulmonary phenotypic manifestations also provide a window into the early consequences of this genetic disorder. For these reasons, the National Heart, Lung, and Blood Institute (NHLBI) convened a working group of extramural experts, entitled "Future Research Directions in Early CF Lung Disease"on September 21-22, 2010, to identify future research directions of great promise in CF. The priority areas identified included (1) exploring pathogenic mechanisms of early CF lung disease; (2) leveraging newborn screening to elucidate the natural history of early lung disease; (3) developing a spectrum of biomarkers of early lung disease that reflects CF pathophysiology, clinical outcome, and response to treatment; (4) exploring the role of genetics/genomics (e.g., modifier genes, gene - environmental interactions, and epigenetics) in early CF pathogenesis; (5) defining early microbiological events in CF lung disease; and (6) elucidating the initial airway inflammatory, remodeling, and repair mechanisms in CF lung disease.

Original languageEnglish (US)
Pages (from-to)887-892
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume185
Issue number8
DOIs
StatePublished - Apr 15 2012

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Cystic Fibrosis
Lung Diseases
Education
Research
Cystic Fibrosis Transmembrane Conductance Regulator
Direction compound
Modifier Genes
Airway Remodeling
Inborn Genetic Diseases
Regulator Genes
Genomics
Epigenomics
Animal Models
Biomarkers

Keywords

  • Airway disease
  • Cystic fibrosis
  • Genetics
  • Innate immunity
  • Microbiology

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Future directions in early cystic fibrosis lung disease research : An NHLBI workshop report. / Ramsey, Bonnie W.; Banks-Schlegel, Susan; Accurso, Frank J.; Boucher, Richard C.; Cutting, Garry R; Engelhardt, John F.; Guggino, William B; Karp, Christopher L.; Knowles, Michael R.; Kolls, Jay K.; LiPuma, John J.; Lynch, Susan; McCray, Paul B.; Rubenstein, Ronald C.; Singh, Pradeep K.; Sorscher, Eric; Welsh, Michael.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 185, No. 8, 15.04.2012, p. 887-892.

Research output: Contribution to journalArticle

Ramsey, BW, Banks-Schlegel, S, Accurso, FJ, Boucher, RC, Cutting, GR, Engelhardt, JF, Guggino, WB, Karp, CL, Knowles, MR, Kolls, JK, LiPuma, JJ, Lynch, S, McCray, PB, Rubenstein, RC, Singh, PK, Sorscher, E & Welsh, M 2012, 'Future directions in early cystic fibrosis lung disease research: An NHLBI workshop report', American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 8, pp. 887-892. https://doi.org/10.1164/rccm.201111-2068WS
Ramsey, Bonnie W. ; Banks-Schlegel, Susan ; Accurso, Frank J. ; Boucher, Richard C. ; Cutting, Garry R ; Engelhardt, John F. ; Guggino, William B ; Karp, Christopher L. ; Knowles, Michael R. ; Kolls, Jay K. ; LiPuma, John J. ; Lynch, Susan ; McCray, Paul B. ; Rubenstein, Ronald C. ; Singh, Pradeep K. ; Sorscher, Eric ; Welsh, Michael. / Future directions in early cystic fibrosis lung disease research : An NHLBI workshop report. In: American Journal of Respiratory and Critical Care Medicine. 2012 ; Vol. 185, No. 8. pp. 887-892.
@article{22599b36db534e55bd6e76d13db01227,
title = "Future directions in early cystic fibrosis lung disease research: An NHLBI workshop report",
abstract = "Since the 1989 discovery that mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF), there has been substantial progress toward understanding the molecular basis for CF lung disease, leading to the discovery and development of new therapeutic approaches. However, the earliest impact of the loss of CFTR function on airway physiology and structure and its relationship to initial infection and inflammation are poorly understood. Universal newborn screening for CF in the United States represents an unprecedented opportunity for investigating CF clinical manifestations very early in life. Recently developed animal models with pulmonary phenotypic manifestations also provide a window into the early consequences of this genetic disorder. For these reasons, the National Heart, Lung, and Blood Institute (NHLBI) convened a working group of extramural experts, entitled {"}Future Research Directions in Early CF Lung Disease{"}on September 21-22, 2010, to identify future research directions of great promise in CF. The priority areas identified included (1) exploring pathogenic mechanisms of early CF lung disease; (2) leveraging newborn screening to elucidate the natural history of early lung disease; (3) developing a spectrum of biomarkers of early lung disease that reflects CF pathophysiology, clinical outcome, and response to treatment; (4) exploring the role of genetics/genomics (e.g., modifier genes, gene - environmental interactions, and epigenetics) in early CF pathogenesis; (5) defining early microbiological events in CF lung disease; and (6) elucidating the initial airway inflammatory, remodeling, and repair mechanisms in CF lung disease.",
keywords = "Airway disease, Cystic fibrosis, Genetics, Innate immunity, Microbiology",
author = "Ramsey, {Bonnie W.} and Susan Banks-Schlegel and Accurso, {Frank J.} and Boucher, {Richard C.} and Cutting, {Garry R} and Engelhardt, {John F.} and Guggino, {William B} and Karp, {Christopher L.} and Knowles, {Michael R.} and Kolls, {Jay K.} and LiPuma, {John J.} and Susan Lynch and McCray, {Paul B.} and Rubenstein, {Ronald C.} and Singh, {Pradeep K.} and Eric Sorscher and Michael Welsh",
year = "2012",
month = "4",
day = "15",
doi = "10.1164/rccm.201111-2068WS",
language = "English (US)",
volume = "185",
pages = "887--892",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "8",

}

TY - JOUR

T1 - Future directions in early cystic fibrosis lung disease research

T2 - An NHLBI workshop report

AU - Ramsey, Bonnie W.

AU - Banks-Schlegel, Susan

AU - Accurso, Frank J.

AU - Boucher, Richard C.

AU - Cutting, Garry R

AU - Engelhardt, John F.

AU - Guggino, William B

AU - Karp, Christopher L.

AU - Knowles, Michael R.

AU - Kolls, Jay K.

AU - LiPuma, John J.

AU - Lynch, Susan

AU - McCray, Paul B.

AU - Rubenstein, Ronald C.

AU - Singh, Pradeep K.

AU - Sorscher, Eric

AU - Welsh, Michael

PY - 2012/4/15

Y1 - 2012/4/15

N2 - Since the 1989 discovery that mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF), there has been substantial progress toward understanding the molecular basis for CF lung disease, leading to the discovery and development of new therapeutic approaches. However, the earliest impact of the loss of CFTR function on airway physiology and structure and its relationship to initial infection and inflammation are poorly understood. Universal newborn screening for CF in the United States represents an unprecedented opportunity for investigating CF clinical manifestations very early in life. Recently developed animal models with pulmonary phenotypic manifestations also provide a window into the early consequences of this genetic disorder. For these reasons, the National Heart, Lung, and Blood Institute (NHLBI) convened a working group of extramural experts, entitled "Future Research Directions in Early CF Lung Disease"on September 21-22, 2010, to identify future research directions of great promise in CF. The priority areas identified included (1) exploring pathogenic mechanisms of early CF lung disease; (2) leveraging newborn screening to elucidate the natural history of early lung disease; (3) developing a spectrum of biomarkers of early lung disease that reflects CF pathophysiology, clinical outcome, and response to treatment; (4) exploring the role of genetics/genomics (e.g., modifier genes, gene - environmental interactions, and epigenetics) in early CF pathogenesis; (5) defining early microbiological events in CF lung disease; and (6) elucidating the initial airway inflammatory, remodeling, and repair mechanisms in CF lung disease.

AB - Since the 1989 discovery that mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause cystic fibrosis (CF), there has been substantial progress toward understanding the molecular basis for CF lung disease, leading to the discovery and development of new therapeutic approaches. However, the earliest impact of the loss of CFTR function on airway physiology and structure and its relationship to initial infection and inflammation are poorly understood. Universal newborn screening for CF in the United States represents an unprecedented opportunity for investigating CF clinical manifestations very early in life. Recently developed animal models with pulmonary phenotypic manifestations also provide a window into the early consequences of this genetic disorder. For these reasons, the National Heart, Lung, and Blood Institute (NHLBI) convened a working group of extramural experts, entitled "Future Research Directions in Early CF Lung Disease"on September 21-22, 2010, to identify future research directions of great promise in CF. The priority areas identified included (1) exploring pathogenic mechanisms of early CF lung disease; (2) leveraging newborn screening to elucidate the natural history of early lung disease; (3) developing a spectrum of biomarkers of early lung disease that reflects CF pathophysiology, clinical outcome, and response to treatment; (4) exploring the role of genetics/genomics (e.g., modifier genes, gene - environmental interactions, and epigenetics) in early CF pathogenesis; (5) defining early microbiological events in CF lung disease; and (6) elucidating the initial airway inflammatory, remodeling, and repair mechanisms in CF lung disease.

KW - Airway disease

KW - Cystic fibrosis

KW - Genetics

KW - Innate immunity

KW - Microbiology

UR - http://www.scopus.com/inward/record.url?scp=84860115099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860115099&partnerID=8YFLogxK

U2 - 10.1164/rccm.201111-2068WS

DO - 10.1164/rccm.201111-2068WS

M3 - Article

C2 - 22312017

AN - SCOPUS:84860115099

VL - 185

SP - 887

EP - 892

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 8

ER -